Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Anti N1 cross-protecting antibodies against H5N1 detected in H1N1 infected people.

Frobert E, Bouscambert-Duchamp M, Escuret V, Mundweiler S, Barthélémy M, Morfin F, Valette M, Gerdil C, Lina B, Ferraris O.

Curr Microbiol. 2010 Jul;61(1):25-8. doi: 10.1007/s00284-009-9571-z. Epub 2009 Dec 25.

PMID:
20033691
2.

Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.

Desheva YA, Smolonogina TA, Donina SA, Rudenko LG.

BMC Res Notes. 2015 Apr 10;8:136. doi: 10.1186/s13104-015-1086-z.

3.

A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.

Wu CY, Yeh YC, Chan JT, Yang YC, Yang JR, Liu MT, Wu HS, Hsiao PW.

PLoS One. 2012;7(8):e42363. doi: 10.1371/journal.pone.0042363. Epub 2012 Aug 7.

4.

Pre-existing cross-reactive antibodies to avian influenza H5N1 and 2009 pandemic H1N1 in US military personnel.

Pichyangkul S, Krasaesub S, Jongkaewwattana A, Thitithanyanont A, Wiboon-Ut S, Yongvanitchit K, Limsalakpetch A, Kum-Arb U, Mongkolsirichaikul D, Khemnu N, Mahanonda R, Garcia JM, Mason CJ, Walsh DS, Saunders DL.

Am J Trop Med Hyg. 2014 Jan;90(1):149-52. doi: 10.4269/ajtmh.13-0151. Epub 2013 Nov 25.

5.

Induction of cross-neutralizing antibody against H5N1 virus after vaccination with seasonal influenza vaccine in COPD patients.

Kositanont U, Wongsurakiat P, Pooruk P, Maranetra N, Puthavathana P.

Viral Immunol. 2010 Jun;23(3):329-34. doi: 10.1089/vim.2009.0082.

PMID:
20565296
6.

Protection against H5N1 highly pathogenic avian and pandemic (H1N1) 2009 influenza virus infection in cynomolgus monkeys by an inactivated H5N1 whole particle vaccine.

Nakayama M, Shichinohe S, Itoh Y, Ishigaki H, Kitano M, Arikata M, Pham VL, Ishida H, Kitagawa N, Okamatsu M, Sakoda Y, Ichikawa T, Tsuchiya H, Nakamura S, Le QM, Ito M, Kawaoka Y, Kida H, Ogasawara K.

PLoS One. 2013 Dec 23;8(12):e82740. doi: 10.1371/journal.pone.0082740. eCollection 2013.

7.

Determination of serum neutralization antibodies against seasonal influenza A strain H3N2 and the emerging strains 2009 H1N1 and avian H5N1.

Zhang R, Rong X, Pan W, Peng T.

Scand J Infect Dis. 2011 Mar;43(3):216-20. doi: 10.3109/00365548.2010.539258. Epub 2010 Dec 9.

PMID:
21142624
8.

Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine.

Qiu C, Huang Y, Wang Q, Tian D, Zhang W, Hu Y, Yuan Z, Zhang X, Xu J.

Clin Infect Dis. 2012 Jan 1;54(1):17-24. doi: 10.1093/cid/cir753. Epub 2011 Nov 3.

9.

Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus.

Van Reeth K, Braeckmans D, Cox E, Van Borm S, van den Berg T, Goddeeris B, De Vleeschauwer A.

Vaccine. 2009 Oct 23;27(45):6330-9. doi: 10.1016/j.vaccine.2009.03.021.

PMID:
19840669
10.

Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.

van der Velden MV, Geisberger A, Dvorak T, Portsmouth D, Fritz R, Crowe BA, Herr W, Distler E, Wagner EM, Zeitlinger M, Sauermann R, Stephan C, Ehrlich HJ, Barrett PN, Aichinger G.

Clin Vaccine Immunol. 2014 Jun;21(6):867-76. doi: 10.1128/CVI.00065-14. Epub 2014 Apr 16.

11.

Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial.

Bethell D, Saunders D, Jongkaewwattana A, Kramyu J, Thitithayanont A, Wiboon-ut S, Yongvanitchit K, Limsalakpetch A, Kum-Arb U, Uthaimongkol N, Garcia JM, Timmermans AE, Peiris M, Thomas S, Engering A, Jarman RG, Mongkolsirichaikul D, Mason C, Khemnu N, Tyner SD, Fukuda MM, Walsh DS, Pichyangkul S.

PLoS One. 2013;8(3):e59674. doi: 10.1371/journal.pone.0059674. Epub 2013 Mar 26.

12.

An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.

Zhao G, Sun S, Du L, Xiao W, Ru Z, Kou Z, Guo Y, Yu H, Jiang S, Lone Y, Zheng BJ, Zhou Y.

Virol J. 2010 Jul 12;7:151. doi: 10.1186/1743-422X-7-151.

13.

Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.

Lu X, Liu F, Zeng H, Sheu T, Achenbach JE, Veguilla V, Gubareva LV, Garten R, Smith C, Yang H, Stevens J, Xu X, Katz JM, Tumpey TM.

Virology. 2014 Apr;454-455:169-75. doi: 10.1016/j.virol.2014.02.011. Epub 2014 Mar 5.

14.

Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses.

Wan H, Gao J, Xu K, Chen H, Couzens LK, Rivers KH, Easterbrook JD, Yang K, Zhong L, Rajabi M, Ye J, Sultana I, Wan XF, Liu X, Perez DR, Taubenberger JK, Eichelberger MC.

J Virol. 2013 Aug;87(16):9290-300. doi: 10.1128/JVI.01203-13. Epub 2013 Jun 19.

15.

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ.

PLoS Med. 2007 Feb;4(2):e59.

16.

Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.

Ahmed MS, Jacques LC, Mahallawi W, Ferrara F, Temperton N, Upile N, Vaughan C, Sharma R, Beer H, Hoschler K, McNamara PS, Zhang Q.

Antiviral Res. 2015 Feb;114:106-12. doi: 10.1016/j.antiviral.2014.12.008. Epub 2014 Dec 13.

PMID:
25513756
17.

Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.

Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC.

J Virol. 2015 Jul;89(14):7224-34. doi: 10.1128/JVI.00585-15. Epub 2015 May 6.

18.

Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus.

Ding H, Tsai C, Zhou F, Buchy P, Deubel V, Zhou P.

PLoS One. 2011 Mar 25;6(3):e17821. doi: 10.1371/journal.pone.0017821.

19.

Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.

Zhu H, Ding X, Chen X, Yao P, Xu F, Xie R, Yang Z, Liang W, Zhang Y, Li Y, Shen J, He P, Guo Z, Su B, Sun S, Zhu Z.

Vaccine. 2011 Jul 26;29(33):5421-3. doi: 10.1016/j.vaccine.2011.05.067. Epub 2011 Jun 7.

PMID:
21645575
20.

Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.

Budimir N, Huckriede A, Meijerhof T, Boon L, Gostick E, Price DA, Wilschut J, de Haan A.

PLoS One. 2012;7(1):e30898. doi: 10.1371/journal.pone.0030898. Epub 2012 Jan 27.

Supplemental Content

Support Center